Publicaciones científicas

Acute generalized exanthematous pustulosis induced by sorafenib

01-jun-2014 | Revista: JAMA Dermatology

Pretel M1, Iñarrairaegui M 1, Lera JM1, Idoate MA2 1Department of Dermatology, School of Medicina, University Clinic of Navarra, Pamplona, Spain
2Department of Pathology, School of Medicina, University Clinic of Navarra, Pamplona, Spain


Ver artículo completo

Sorafenib (Nexavar; Bayer HealthCare AG) is an oral multikinase inhibitor approved by the US Food and Drug Administration for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. It inhibits multiple tyrosine kinases, including C-RAF and B-RAF, vascular endothelial growth factor receptors, and platelet-derived growth factor receptor (PDGFR).

Acute generalized exanthematous pustulosis (AGEP) is a rare skin eruption associated principally with drugs. To our knowledge, only 1 report of sorafenib-induced acute localized exanthematous pustulosis (ALEP) has been published. Herein, we report the first case of AGEP induced by sorafenib.

CITA DEL ARTÍCULO   JAMA Dermatol. 2014 Jun 1;150(6):664-6. doi: 10.1001/jamadermatol.2013.6924.